TY - JOUR
T1 - The global Alzheimer's Association round robin study on plasma amyloid β methods
AU - Pannee, Josef
AU - Shaw, Leslie M.
AU - Korecka, Magdalena
AU - Waligorska, Teresa
AU - Teunissen, Charlotte E.
AU - Stoops, Erik
AU - Vanderstichele, Hugo M. J.
AU - Mauroo, Kimberley
AU - Verberk, Inge M. W.
AU - Keshavan, Ashvini
AU - Pesini, Pedro
AU - Sarasa, Leticia
AU - Pascual-Lucas, Maria
AU - Fandos, Noelia
AU - Allué, José-Antonio
AU - Portelius, Erik
AU - Andreasson, Ulf
AU - Yoda, Ritsuko
AU - Nakamura, Akinori
AU - Kaneko, Naoki
AU - Yang, Shieh-Yueh
AU - Liu, Huei-Chun
AU - Palme, Stefan
AU - Bittner, Tobias
AU - Mawuenyega, Kwasi G.
AU - Ovod, Vitaliy
AU - Bollinger, James
AU - Bateman, Randall J.
AU - Li, Yan
AU - Dage, Jeffrey L.
AU - Stomrud, Erik
AU - Hansson, Oskar
AU - Schott, Jonathan M.
AU - Blennow, Kaj
AU - Zetterberg, Henrik
N1 - © 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.
PY - 2021
Y1 - 2021
N2 - Introduction: Blood-based assays to measure brain amyloid beta (Aβ) deposition are an attractive alternative to the cerebrospinal fluid (CSF)–based assays currently used in clinical settings. In this study, we examined different blood-based assays to measure Aβ and how they compare among centers and assays. Methods: Aliquots from 81 plasma samples were distributed to 10 participating centers. Seven immunological assays and four mass-spectrometric methods were used to measure plasma Aβ concentrations. Results: Correlations were weak for Aβ42 while Aβ40 correlations were stronger. The ratio Aβ42/Aβ40 did not improve the correlations and showed weak correlations. Discussion: The poor correlations for Aβ42 in plasma might have several potential explanations, such as the high levels of plasma proteins (compared to CSF), sensitivity to pre-analytical sample handling and specificity, and cross-reactivity of different antibodies. Different methods might also measure different pools of plasma Aβ42. We, however, hypothesize that greater correlations might be seen in future studies because many of the methods have been refined during completion of this study.
AB - Introduction: Blood-based assays to measure brain amyloid beta (Aβ) deposition are an attractive alternative to the cerebrospinal fluid (CSF)–based assays currently used in clinical settings. In this study, we examined different blood-based assays to measure Aβ and how they compare among centers and assays. Methods: Aliquots from 81 plasma samples were distributed to 10 participating centers. Seven immunological assays and four mass-spectrometric methods were used to measure plasma Aβ concentrations. Results: Correlations were weak for Aβ42 while Aβ40 correlations were stronger. The ratio Aβ42/Aβ40 did not improve the correlations and showed weak correlations. Discussion: The poor correlations for Aβ42 in plasma might have several potential explanations, such as the high levels of plasma proteins (compared to CSF), sensitivity to pre-analytical sample handling and specificity, and cross-reactivity of different antibodies. Different methods might also measure different pools of plasma Aβ42. We, however, hypothesize that greater correlations might be seen in future studies because many of the methods have been refined during completion of this study.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85124416442&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/34692980
U2 - https://doi.org/10.1002/dad2.12242
DO - https://doi.org/10.1002/dad2.12242
M3 - Article
C2 - 34692980
SN - 2352-8729
VL - 13
JO - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
JF - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
IS - 1
M1 - e12242
ER -